Trial document



drksid header

  DRKS00006078

Trial Description

start of 1:1-Block title

Title

Determination of blood volume and hemoglobin mass using the optimised carbon monoxide rebreathing method in clinical patients - cardiac failure or situation post cardiac transplant

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Regulation of fluid balance is of major importance in patients with chronic cardiac failure with reduced systolic function. Total blood volume plays a special role here as it can be further differentiated into its components plasma volume and red cell volume. The implications of plasma volume are not fully understood, especially when regarding situations with coexistent anemia (meaning a Hemoglobin concentration below a certain threshold, e.g. 13.0 g/dl for males according to the WHO definition).
Anemia of patients with cardiac failure is associated with increased mortality and reduced physical performance.
As Hb is a concentration value, depending on plasma volume, aim of this study is to determine total hemoglobin mass, or red cell volume, respectively in a direct ways to better understand regulation of blood volume and erythropoiesis.
Various methods exist to determine these parameters, the majority time consuming and partly depend on application of radioactive tracers. The so called optimized CO rebreathing method is a method to determine the parameters within one our. Its application in clinical patients was approved by the local board's ethics committee in 2006.
Our current goal is to use the methods in patients with chronic cardiac failure or with situation post heart transplant and compare these groups with healthy controls to better understand regulation of blood volume when ventricular function is reduce. We aim at paying special attention to anemia, as the occurrence of anemia in this patient group is not fully understood and might also due to hemodilution due to an increase plasma volume. Moreover, our study aims at adapting the formulas on which the CO-rebreathing method is based to the special cardiovascular situation of patients with cardiac failure in order to provide a suitable routine tool for blood volume detection in this clinical group.

Arm 3 added MitraClip group (University Freiburg Ethics board approval 31/14, Act 171480)

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

With our study we are aiming to understand anemia in patients with chronic heart failure better. As conventional parameters of FBC (e.g. hemoglobin concentration) may be affected by hemodilution e.g. through an expanded plasma volume, we aim at measuring the vascular parameters in absolute terms (total hemoglobin mass of the body). The optimised CO-rebreathing be a suitable tool for determination of Hb mass, however, it results might be affected by cardiovascular properties of the patient.
Our goal with this study is to apply this method to a collective of heart failure patients in order to learn about the applicability of this methods in this patient group, to understand origin of anemia in this group better and to study the influence of physical activity on the measures provided above.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006078
  •   2014/05/09
  •   [---]*
  •   yes
  •   Approved
  •   31/14, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   I50.1 -  Left ventricular failure
  •   D63.8 -  Anaemia in other chronic diseases classified elsewhere
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Key population (cross-sectional study part): chronic cardiac failure with at least mildly reduced systolic LV-function (EF≤ 45%), of various etiologie, e.g. ischemic, dilated, inflammatory. Or normal LV-function in patients s/p heart transplant in stable cardiovascular situation.

    In addition to the standard therapy, one determination of hemoglobin mass through the optimised CO-rebreathing method will be conducted.
  •   Physical activity group (longitudinal study): as above but with physical activity of at least 150min / wk (e.g. trough participating in cardiac sports group, or home based training e.g. strolling, nordic walking).

    In addition to the standard therapy, serial determinations of hemoglobin mass through the optimised CO-rebreathing method will be conducted.
  •   MitraClip group. Measurement of the study parameters in a subgroup of CHF patients with severe mitral regurgitation after decision for Mitraclip procedure.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Other
  •   Other
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Basic research/physiological study
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Hemoglobin mass measured using the optimised carbon monoxide rebreathing method in patients with different stages of left ventricular failure

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Influence of physical activity on hemoglobin mass.
- Relation between hemoglobin mass and FBC, Iron status

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2014/05/01
  •   150
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Main study population (cross-sectional analysis): chronic cardiac failure with at least a moderately reduced LV function (EF<45%), of various origin, e.g. ischemic, dilated, inflammatory. Or preserved LV function when situation post heart transplant.
Phycial acitivity group (longitudinal analysis): as above but with a weekly physical activity of at least 150min, e.g. through participation in cardiac sports group, nordic walking, strolling

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- patients with acute coronary syndrome without intervention - life expectation of less than one year because of a non-cardial disease - current onconlogic disease - acute infection (e.g. pneumonia) - evidence for acute transplant failure - chronic inflammatory diseases - relevant chronic kidney disease of non cardiac origin - anemia of origin other than cardiac e.g. chronic intestinal hemorrhage - [♀Hb] < 8g/dl - current use of erythropoietic growth factors - patients featuring a lung function that does not allow participation in a rebreathing procedure from a clinical aspect - people that cannot participate in the study because of a lack of compliance, based on the judgement of the study doctors - chronic alkohol or drug abuse - those who are not able or not willing to give an informed consent to participate in the study

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinik FreiburgInstitut für Arbeits- und Bewegungsmedizin
    • Mr.  PD Dr. med.  Torben  Pottgiesser 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Universitätsklinik FreiburgInstitut für Arbeits- und Bewegungsmedizin
    • Mr.  Dr.  Christoph  Ahlgrim 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Universitätsklinik FreiburgInstitut für Bewegungs- und Arbeitsmedizin
    • Mr.  PD Dr.  Torben  Pottgiesser 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Uniklinik FreiburgInstitut für Arbeits- und Bewegungsmedizin
    • Mr.  PD Dr.  Torben  Pottgiesser 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Universitäts Herzzentrum Freiburg - Bad Krozingen
    • Mr. 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Universitaetsklinik FreiburgInstitut für Bewegungs und Arbeitsmedizin
    • Mr.  Dr. med.  Christoph  Ahlgrim 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.